Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics is set to move its lead drug candidate, CardiolRx™, into a late-stage trial for recurrent pericarditis, a heart condition with high recurrence rates. The MAVERIC-2 trial aims to explore the drug’s impact after patients stop using costly interleukin-1 blockers, potentially offering a non-immunosuppressive alternative. This development could expand CardiolRx’s market potential and accelerate its path to regulatory approval.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
